Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/kisup.2013.90

http://scihub22266oqcxt.onion/10.1038/kisup.2013.90
suck pdf from google scholar
25028644!4089624!25028644
unlimited free pdf from europmc25028644    free
PDF from PMC    free
html from PMC    free
PDF vom PMID25028644  :  Publisher
PDF vom PMID25028644 :   free

suck abstract from ncbi

pmid25028644
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Calcimimetics and outcomes in CKD #MMPMID25028644
  • Drueke TB
  • Kidney Int Suppl (2011) 2013[Dec]; 3 (5): 431-435 PMID25028644show ga
  • In the past decade, several experimental studies demonstrated an inhibitory effect of calcimimetics on the progression of vascular calcification in animals with chronic kidney disease (CKD), in keeping with the expression of the calcium-sensing receptor (CaR) in vascular tissue. In addition, calcimimetics were also found to prevent the arterial remodeling caused by CKD and to slow the progression of atherosclerosis in uremic rats and mice, respectively. The mode of action of these CaR modulators could be both via a better control of secondary hyperparathyroidism and direct effects on the vessel wall. Two main clinical trials, ADVANCE and EVOLVE, recently evaluated in patients with CKD stage 5D the effects of the calcimimetic cinacalcet on the progression of vascular calcification and hard cardiovascular outcomes, respectively. Both trials missed their respective primary end point by intent-to-treat analysis although by other prespecified analyses, including adjustment for baseline characteristics, there was strong suggestive evidence in favor of reductions in risk, in agreement with numerous experimental studies. Further clinical trials are needed to settle this issue definitively.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    431 5.3 2013